Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway

• Main Authors: Lei Wang (Author), Wuxiyar Otkur (Author), Aman Wang (Author), Wen Wang (Author), Yitong Lyu (Author), Lei Fang (Author), Xiu Shan (Author), Mingzhou Song (Author), Yan Feng (Author), Yi Zhao (Author), Hai-Long Piao (Author), Huan Qi (Author), Ji-Wei Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Melanoma is the most aggressive type of skin cancer with a high incidence and low survival rate. More than half of melanomas present the activating BRAF mutations, along which V600E mutant represents 70%-90%. Vemurafenib (Vem) is an FDA-approved small-molecule kinase inhibitor that selectively targe...